08-Oct-2020: 4DMedical Goldman Sachs Healthcare Forum Presentation
The COVID-19 pandemic should be giving a company like 4DX a decent boost, i.e. providing them with a strong tailwind, considering they specialise in digital four-dimensional lung imaging and data interpretation. They rose +14.11% today on the back of this presentation at the Goldman Sachs Healthcare Forum.
Introduction to 4DMedical
- Founded in 2012, 4DMedical Limited is a Melbourne-based software technology company focused on creating a step change in the capacity of physicians to diagnose and manage patients with diseases of the lung
- The respiratory diagnostic sector represents a global market of over US$31 billion per annum, with over 377 million respiratory diagnostics tests performed each year
- 4DMedical is focused on commercialising its four-dimensional XV lung imaging technology, which utilises proven, patented algorithms to convert X-ray images into quantitative scan data
- Unlike existing respiratory diagnostic procedures, 4DMedical’s proprietary XV technology provides a non-invasive way of understanding regional lung motion and airflow in real-time
- With FDA clearance in place, 4DMedical’s major focus is on US market commercialisation of its XV Technology
- Australian TGA approval for XV Lung Ventilation Analysis Software (LVAS) allows 4DMedical to gain local traction quickly through leveraging existing industry knowledge and relationships
- The SaaS business model offers hospitals access to the technology without the traditional issues of hardware integration, capex, additional staff or re-training
- 4DMedical’s advancement in respiratory diagnostic technology is expected to result in improved patient experiences, earlier intervention leading to improved healthcare outcomes, with reduced costs of care
[I'm not a shareholder, but they look interesting. I would need to do more work before investing, such as establishing whether they have a credible path to profitability within a reasonable and realistic timeframe.]
